Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 김경효 | * |
| dc.date.accessioned | 2026-04-09T16:31:10Z | - |
| dc.date.available | 2026-04-09T16:31:10Z | - |
| dc.date.issued | 2026 | * |
| dc.identifier.issn | 0095-1137 | * |
| dc.identifier.other | OAK-39191 | * |
| dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/275127 | - |
| dc.description.abstract | Streptococcus pneumoniae (pneumococcus) is a leading cause of community-acquired pneumonia and invasive diseases, particularly among children and the elderly. The introduction of pneumococcal conjugate vaccines has significantly reduced invasive pneumococcal disease, but the prevalence of non-vaccine serotypes and newly emerging serotypes is increasing globally. Thus, accurate serotyping is essential for epidemiological surveillance and the development of next-generation multivalent pneumococcal vaccines. Conventional serotyping methods, including multiplex polymerase chain reaction (mPCR), monoclonal antibody (mAb) assays, and Quellung reaction using rabbit antisera, are limited by serotype coverage and cross-reactivity, making the detection of new or emerging serotypes challenging. In this study, we developed a nanopore Cas9-targeted serotyping (nCATSerotyping) platform, which employs Cas9-mediated enrichment of the capsular polysaccharide synthesis locus followed by Oxford Nanopore sequencing. Applying this method to 276 clinical pneumococcal isolates collected in South Korea (2018–2020), we achieved a serotyping success rate of 97.10% (268∕276), significantly outperforming conventional methods such as mAb and mPCR, which identified only 76.45% (211∕276) of isolates. Whole-genome sequencing of the remaining eight non-typeable isolates revealed them to be non-pneumococcal (oral streptococci), confirming 100% accuracy for S. pneumoniae serotyping. Importantly, our method identified emerging and underrepresented serotypes, including serotype 13 and null capsule clade strains. nCATSerotyping offers a rapid, accurate, and comprehensive solution for pneumococcal serotyping, with significant advantages in identifying novel and non-typeable strains. This scalable platform will be a valuable tool for global serotype surveillance and next-generation multivalent pneumococcal vaccine development. Copyright © 2025 Ji et al. | * |
| dc.description.sponsorship | American Society for Microbiology | * |
| dc.language | English | * |
| dc.subject | CRISPR-Cas9 | * |
| dc.subject | emerging serotypes | * |
| dc.subject | nanopore sequencing | * |
| dc.subject | serotyping | * |
| dc.subject | Streptococcus pneumoniae | * |
| dc.subject | vaccine development | * |
| dc.title | Accurate serotype identification of Streptococcus pneumoniae using nanopore Cas9-targeted serotype identification (nCATSerotyping) | * |
| dc.type | Article | * |
| dc.relation.issue | 2 | * |
| dc.relation.volume | 64 | * |
| dc.relation.index | SCIE | * |
| dc.relation.index | SCOPUS | * |
| dc.relation.journaltitle | Journal of Clinical Microbiology | * |
| dc.identifier.doi | 10.1128/jcm.00984-25 | * |
| dc.identifier.wosid | WOS:001650953200001 | * |
| dc.identifier.scopusid | 2-s2.0-105029922906 | * |
| dc.author.google | Ji H.J. | * |
| dc.author.google | A-Yeung J. | * |
| dc.author.google | Han S.H. | * |
| dc.author.google | Kim M.-K. | * |
| dc.author.google | Lamien C.E. | * |
| dc.author.google | Wijewardana V. | * |
| dc.author.google | Ahn K.B. | * |
| dc.author.google | Kim K.-H. | * |
| dc.author.google | Song J.Y. | * |
| dc.author.google | Seo H.S. | * |
| dc.contributor.scopusid | 김경효(35448653000) | * |
| dc.date.modifydate | 20260615164147 | * |